Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03IVC
|
|||
| Former ID |
DNC001248
|
|||
| Drug Name |
S 202 791
|
|||
| Synonyms |
Sandoz-202-791; Sdz 202-791; SAN 202791; R202-791; S 202-791; 97217-84-0; C17H18N4O5; 3-Pyridinecarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-5-nitro-, 1-methylethyl ester, (R)-; (R)-Sandoz 202-791; (-)-Sandoz 202-791; Sandoz 202-791, (-)-; (R)-(-)-Sandoz 202-791; AC1L3UBJ; AC1Q1WKA; (-)-SDZ 202-791; CBiol_001888; (-)-PN 202-791; CHEMBL487115; (R)-202-791; CTK5H9159; Bio1_001152; Bio1_000174; Bio1_000663; AKOS030532582; SDZ-202791; SDZ-202-791; NCGC00163134-01; 3-Pyridinecarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18N4O5
|
|||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC3=NON=C32)C(=O)OC(C)C
|
|||
| InChI |
1S/C17H18N4O5/c1-8(2)25-17(22)13-9(3)18-10(4)16(21(23)24)14(13)11-6-5-7-12-15(11)20-26-19-12/h5-8,14,18H,1-4H3/t14-/m1/s1
|
|||
| InChIKey |
LYFZEFDZKPJBJK-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 97217-84-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated L-type calcium channel (L-CaC) | Target Info | Activator | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.